MNPR

MONOPAR THERAPEUTICS INC

MNPR·61023L207·US·Common Stock·Healthcare - Biotechnology-Activist

MNPR (MONOPAR THERAPEUTICS INC) is held by 64 institutional investors as of Q2 2026. Largest holders: RA CAPITAL MANAGEMENT, L.P. ($61.8M), BlackRock, Inc. ($32.3M), Polar Capital Holdings Plc ($19.9M). Net institutional sentiment: Mixed.

64
Holders
(5 Elite)
$283M
Total Value
62% (66)
Consensus
41 buying - 25 selling
13F: Insider & Congress: Updated regularly
MNPR

Smart Money Verdict

View all
Loading verdict
Held by 64 funds
5 elite

Who's Trading

Source dates: Price Aug 28, 2026 · Insiders Aug 28, 2026 · Activists Aug 12, 2026 · Congress none

InsiderTRTsuchimoto Kim RSell $53KAug 26, 2026
InsiderTRTsuchimoto Kim RSell $123KAug 26, 2026
InsiderTRTsuchimoto Kim RExercise 2K shAug 26, 2026
Checking access…

Top Holders

Checking access…
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Unchanged
667,207$61.8M0.5%+239.59%
0
Increased
348,819(+10.2%)$32.3M0.0%+143.01%
32
Decreased
214,469(-5.3%)$19.9M0.0%+95.94%
0
Decreased
209,711(-4.0%)$19.4M0.0%+119.20%
0
Decreased
209,195(-32.3%)$19.4M0.0%+297.79%
0
Decreased
158,437(-9.1%)$14.7M0.0%+49.83%
0
New
143,339$13.3M0.1%+22.82%
39
Decreased
134,543(-1.4%)$12.5M0.0%+106.90%
0
Increased
112,578(+12.7%)$10.4M0.0%+173.12%
31
Unchanged
100,000$9.3M0.0%+94.46%
0
Increased
92,551(+4.8%)$8.6M0.0%+102.41%
29
Increased
84,040(+153.5%)$7.8M0.0%+32.22%
44
Decreased
76,942(-2.1%)$7.1M0.0%+88.55%
0
Increased
55,194(+30.1%)$5.1M0.0%+64.65%
34
Decreased
50,311(-5.0%)$4.7M0.0%+81.36%
0
Increased
48,816(+6.2%)$4.5M0.0%+109.66%
29
Decreased
37,004(-36.7%)$3.4M0.0%+114.46%
0
Increased
34,641(+8.7%)$3.2M0.0%+159.28%
29
Increased
31,008(+7.6%)$2.9M0.0%+112.64%
28
Decreased
28,280(-0.6%)$2.6M0.0%+119.20%
0

Showing 1-20 of 71

1 / 4
MNPRMNPRMONOPAR THERAPEUTICS INC

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used